Antithrombotic medication for stroke prevention

References

• Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet367, 1747–1757 (2006).
   PubMed Web of Science ®Google Scholar
• Grau AJ, Weimar C, Buggle F et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke – The German Stroke Data Bank. Stroke32, 2559–2566 (2001).
   PubMed Web of Science ®Google Scholar
• Appelros P, Stegmayr B, Terent A. Sex differences in stroke epidemiology: a systematic review. Stroke40, 1082–1090 (2009).
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc. Dis.16(Suppl. 1), 14–19 (2003).
   PubMed Web of Science ®Google Scholar
• Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol.6, 1063–1072 (2007).
   PubMed Web of Science ®Google Scholar
• Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology62, 569–573 (2004).
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N. Engl. J. Med.321, 129–135 (1989).
   PubMed Web of Science ®Google Scholar
• Peto R, Gray R, Collins R et al. Randomized trial of prophylactic daily aspirin in British male doctors. Brit. Med. J.296, 313–316 (1988).
   PubMed Web of Science ®Google Scholar
• ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study Report 14. JAMA268, 1292–1300 (1992).
   PubMed Web of Science ®Google Scholar
• de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet357, 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al.; Hypertension Optimal Treatment (HOT) Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Iso H, Hennekens CH, Stampfer MJ et al. Prospective study of aspirin use and risk of stroke in women. Stroke30, 1764–1771 (1999).
   PubMed Web of Science ®Google Scholar
• Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am. J. Cardiol.98, 746–750 (2006).
   PubMed Web of Science ®Google Scholar
• Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA295, 306–313 (2006).
   PubMed Web of Science ®Google Scholar
• European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc. Dis.25, 457–507 (2008).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med.354, 1706–1717 (2006).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med.146, 857–867 (2007).
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace8, 651–745 (2006).
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet370, 493–503 (2007).
   PubMed Web of Science ®Google Scholar
• Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet367, 1903–1912 (2006).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Hart RG et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med.360, 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet349, 1569–1581 (1997).
   PubMed Web of Science ®Google Scholar
• CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet349, 1641–1649 (1997).
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischemic stroke. Stroke34, 1571–1572 (2003).
   Google Scholar
• Wong KS, Chen C, Ng PW et al. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomized study. Lancet Neurol.6, 407–413 (2007).
   PubMed Web of Science ®Google Scholar
• Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol.6, 961–969 (2007).
   PubMed Web of Science ®Google Scholar
• The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke31, 601–609 (2000).
   PubMed Web of Science ®Google Scholar
• Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized Phase 2 trial. Stroke36, 880–890 (2005).
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, Effron MB, Torner J et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke39, 87–99 (2008).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ324, 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J. Neurol. Neurosurg. Psychiatr.66, 255 (1999).
   PubMed Web of Science ®Google Scholar
• Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med.353, 2373–2383 (2005).
   PubMed Web of Science ®Google Scholar
• Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA297, 2018–2024 (2007).
   PubMed Web of Science ®Google Scholar
• The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med.325, 1261–1266 (1991).
   PubMed Web of Science ®Google Scholar
• Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatr.54, 1044–1054 (1991).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Easton D, Harrington RA et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation108, 399–406 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345, 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet Neurol.6, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann. Neurol.42, 857–865 (1997).
   PubMed Web of Science ®Google Scholar
• Mohr JP, Thompson JL, Lazar RM et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N. Engl. J. Med.345, 1444–1451 (2001).
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet348, 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet364, 331–337 (2004).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol.49, 1982–1988 (2007).
   PubMed Web of Science ®Google Scholar
• Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci.143, 1–13 (1996).
   PubMed Web of Science ®Google Scholar
• Diener HC, Darius H, Bertrand-Hardy JM, Humphreys M. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int. J. Clin. Pract.55, 162–163 (2001).
   PubMedGoogle Scholar
• Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet367, 1665–1673 (2006).
   PubMed Web of Science ®Google Scholar
• Halkes PH, Gray LJ, Bath PM et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J. Neurol. Neurosurg. Psychiatr.79, 1218–1223 (2008).
   PubMed Web of Science ®Google Scholar
• Sacco RL, Diener HC, Yusuf S et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med.359, 1238–1251 (2008).
   PubMed Web of Science ®Google Scholar
• Weimar C, Diener HC, Alberts MJ et al. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the Reduction of Atherothrombosis for Continued Health (REACH) registry. Stroke40, 350–354 (2009).
   PubMedGoogle Scholar
• Weimar C, Goertler M, Rother J et al. Predictive value of the Essen stroke risk score and ankle brachial index in acute ischemic stroke patients from 85 German stroke units. J. Neurol. Neurosurg. Psychiatr.79, 1339–1343 (2008).
   PubMed Web of Science ®Google Scholar
• Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst. Rev.3, CD004296 (2005).
   Google Scholar
• Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet1, 1215–1220 (1989).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Tan WA, Foody JM, Topol EJ; EPISTENT Investigators. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA281, 806–810 (1999).
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Richardson D, Kelly M et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA289, 2947–2957 (2003).
   PubMed Web of Science ®Google Scholar
• Huang Y, Cheng Y, Wu J et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized, double-blind, pilot study. Lancet Neurol.7, 494–499 (2008).
   PubMed Web of Science ®Google Scholar
• Shinohara Y, Nishimaru K, Sawada T et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke39, 1827–1833 (2008).
   PubMed Web of Science ®Google Scholar
• Chimowitz MI, Lynn MJ, Howlett-Smith H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med.352, 1305–1316 (2005).
   PubMed Web of Science ®Google Scholar
• Kwon SU, Cho YJ, Koo JS et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke36, 782–786 (2005).
   PubMed Web of Science ®Google Scholar
• Hagen PT, Scholz DG, Edwards WD. Incidence and size of ER-DP during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin. Proc.59, 17–20 (1984).
   PubMed Web of Science ®Google Scholar
• Meissner I, Whisnant JP, Khandheria BK et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin. Proc.74, 862–869 (1999).
   PubMed Web of Science ®Google Scholar
• Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology55, 1172–1179 (2000).
   PubMed Web of Science ®Google Scholar
• Mas JL, Arquizan C, Lamy C et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N. Engl. J. Med.345, 1740–1746 (2001).
   PubMed Web of Science ®Google Scholar
• Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation105, 2625–2631 (2002).
   PubMed Web of Science ®Google Scholar
• Slottow TL, Steinberg DH, Waksman R. Overview of the 2007 Food and Drug Administration circulatory system devices panel meeting on patent foramen ovale closure devices. Circulation116, 677–682 (2007).
   PubMed Web of Science ®Google Scholar
• European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet342, 1255–1262 (1993).
   PubMed Web of Science ®Google Scholar
• Flaker GC, Gruber M, Connolly SJ et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of Stroke Prevention using an Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) trials. Am. Heart J.152, 967–973 (2006).
   PubMed Web of Science ®Google Scholar
• Radziszewska B, Hart RG, Wolf PA, D’Agostino RB Sr, Cutler JA. Clinical research in primary stroke prevention: needs, opportunities, and challenges. Neuroepidemiology25, 91–104 (2005).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pais P, Afzal R et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a Phase II, double-blind, randomized trial. Lancet373, 1341–1351 (2009).
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke results from the national registry of atrial fibrillation. JAMA285, 2864–2870 (2001).
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest126, S234–S264 (2004).
   PubMed Web of Science ®Google Scholar
• Hart R, Benavente O, McBride R, Pearce L. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med.131, 492–501 (1999).
   PubMed Web of Science ®Google Scholar
• Hart RG, Halperin JL, Pearce LA et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann. Intern. Med.138, 831–838 (2003).
   PubMed Web of Science ®Google Scholar
• Leonardi-Bee J, Bath PM, Bousser MG et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke36, 162–168 (2005).
   PubMed Web of Science ®Google Scholar